EP1702982A1 - Methode de detection, diagnostic et remede contre le cancer du foie - Google Patents

Methode de detection, diagnostic et remede contre le cancer du foie Download PDF

Info

Publication number
EP1702982A1
EP1702982A1 EP04819413A EP04819413A EP1702982A1 EP 1702982 A1 EP1702982 A1 EP 1702982A1 EP 04819413 A EP04819413 A EP 04819413A EP 04819413 A EP04819413 A EP 04819413A EP 1702982 A1 EP1702982 A1 EP 1702982A1
Authority
EP
European Patent Office
Prior art keywords
dlk
antibody
cells
human
liver cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04819413A
Other languages
German (de)
English (en)
Other versions
EP1702982B1 (fr
EP1702982A4 (fr
Inventor
Koji Nakamura
Hiroko Anzai
Hiroyuki Yanai
Atsushi Miyajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanagawa Academy of Science and Technology
Original Assignee
Kanagawa Academy of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Academy of Science and Technology filed Critical Kanagawa Academy of Science and Technology
Priority to EP10003331A priority Critical patent/EP2204448B1/fr
Publication of EP1702982A1 publication Critical patent/EP1702982A1/fr
Publication of EP1702982A4 publication Critical patent/EP1702982A4/fr
Application granted granted Critical
Publication of EP1702982B1 publication Critical patent/EP1702982B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Definitions

  • the present invention relates to a method for detecting liver cancer, diagnostic for liver cancer, and to a therapeutic drug for cancer.
  • Hepatocellular carcinoma is one of the most popular carcinomas in the world, and onset thereof is especially frequent in South East Asia, China, and sub-Saharan Africa. Not less than 30,000 people die for liver cancer in Japan per year, and the number of deaths is still increasing. Most of the liver cancer is hepatocellular carcinoma caused by infection with hepatitis virus. However, the canceration mechanism from viral hepatitis to hepatocellular carcinoma through cirrhosis is still unclear. Therefore, presently used diagnostic methods (ultrasonography, diagnostic imaging by CT, hemodiagnosis using a tumor marker such as ⁇ -fetoprotein) are those targeting already formed cancer tissues.
  • AFP as a tumor marker
  • the specificity to liver cancer is not high, and it is known that AFP level is also high in cirrhosis and hepatitis.
  • liver cancer The mortality rate of cancer in Japan increased from about 1980 and cancer is now the leading cause of death.
  • the number of death from liver cancer is 35,000 per year, which is the third position among the total death by cancers. It is thought that the number of patients of liver cancer will further increase unless an epoch-making diagnostic and therapeutic drug are developed.
  • Current therapies of liver cancer include local treatments such as surgical hepatectomy, percutaneous ethanol-infusion therapy and hepatic arterial embolization, and systemic treatments such as systemic administration of anticancer agents and immunotherapies.
  • the major therapies are local treatments, and hepatectomy is better than percutaneous ethanol-infusion therapy and hepatic arterial embolization in view of cure rate.
  • Non-patent Literature 1 Non-patent Literature 1
  • Picibanil OK-432
  • CHUGAI PHARMACEUTICAL CHUGAI PHARMACEUTICAL
  • cancers Commercialized therapeutic antibodies for cancers include "Herceptin (anti-Her2 humanized monoclonal antibody preparation)” (CHUGAI PHARMACEUTICAL) which is a therapeutic drug for metastatic breast cancer in which excess expression of Her2 is confirmed, and "Rituxan (anti-CD20 chimeric monoclonal antibody preparation) (CHUGAI PHARMACEUTICAL and ZENYAKU KOGYO) which is a therapeutic drug for CD20-positive B-cell type non-Hodgkin lymphoma.
  • These therapeutic antibodies kill cancer cells by immune mechanism such as antibody-dependent cell-mediated cytotoxicity, ADCC) or complement-dependent cytotoxicity, CDC).
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • CDC complement-dependent cytotoxicity
  • Dlk1/Pref-1 is a membrane protein whose extracellular domain has a homology with Notch/Delta/Serrate family.
  • Dlk1/Pref-1 was cloned as a molecule expressing on a cell line derived from lung small cell carcinoma responsive to GRP (gastrin releasing peptide) (Non-patent Literature 1) or as a factor inhibiting differentiation of preadipocyte (Non-patent Literature 2). Its expression is observed in a plurality of tissues and organs during fetal period, but not observed in most of tissues after birth (Non-patent Literatures 2 and 3).
  • Non-patent Literatures 4 and 5 As for the function of Dlk1/Pref-1, in addition to the inhibition of differentiation of preadipocyte, participation in hematopoiesis was suggested recently (Non-patent Literature 6). However, based on the expression pattern and the like, the possibility of participating in maintaining undifferentiated state in undifferentiated cells has been suggested.
  • dlk gene which was highly expressed in the liver of mouse at embryonic day 14.5, by the signal trap method that selectively isolates genes encoding molecules having a signal sequence, that is, those encoding cell surface antigens and secretory proteins.
  • Non-patent Literature 7 Patent Literature 1
  • Non-patent Literature 1 Laborda, J., et al (1993) J. Biol .Chem. 268(6):3817-20
  • Non-patent Literature 2 Smas, C.M., et al (1993) Cell.
  • Non-patent Literature 3 Floridon, C., et al (2000) Differentiation 66(1):49-59
  • Non-patent Literature 4 Harken, J.C., et al (1999) Tumour Biol. 20(5):256-62
  • Non-patent Literature 5 Jensen, C.H., et al (1999) Br. J. Dermatol. 140(6): 1054-9
  • Non-patent Literature 6 Ohno, N., et al (2001) Stem Cells 19(1):71-9
  • Non-patent Literature 7 Tanimizu, N., et al (2003) J. Cell Sci.
  • Non-patent Literature 8 Onishi, M., et al (1996) Exp. Hematol. 24;324-329
  • Non-patent Literature 9 Sell, S. (1993) Int. J. Dev. Biol. 37:189-201
  • Non-patent Literature 10 Jensen, C.H. et al (1994) Eur. J. Biochem. 225:83-92
  • Non-patent Literature 11 Kaneta, M. et al. (2000) J. Immunol. 164:256-264
  • Non-patent Literature 12 Okada, S., et al (1993) Oncology.
  • Patent Literature 1 WO 02/103033
  • the present inventors intensively studied to discover that dlk is expressed on the surfaces of liver cancer cells of adults and experimentally confirmed that liver cancer cells may be detected using the dlk as a tumor marker. Further, the present inventors succeeded in preparing anti-human dlk monoclonal antibodies each of which undergoes antigen-antibody reaction with the extracellular domain of dlk expressing on cell surfaces, and confirmed that each of these anti-human dlk monoclonal antibodies also undergoes antigen-antibody reaction with FA1 which is the extracellular domain of dlk liberated into the blood.
  • the present inventors further inferred that there was a possibility that the anti-human dlk monoclonal antibody may be used as a therapeutic antibody targeting cancer cells expressing Dlk.
  • the present inventors studied anti-tumor activities to specifically kill the cells of cancer cell lines expressing Dlk, of the prepared three anti-human Dlk monoclonal antibodies, using an in vitro experimental system, to confirm the anticancer activity of the anti-human Dlk monoclonal antibodies, thereby completing the present invention.
  • the present invention provides a method for detecting liver cancer cells in a sample, which utilizes as an index expression of dlk gene.
  • the present invention also provides a method for detecting liver cancer, comprising measuring extracellular domain of dlk existing in the blood or urine collected from the body.
  • the present invention further provides a diagnostic for liver cancer, comprising an antibody or an antigen-binding fragment thereof, which undergoes antigen-antibody reaction with extracellular domain of dlk.
  • the present invention still further provides a nucleic acid for detecting liver cancer, which hybridizes with mRNA or cDNA of dlk gene, and which may be used as a primer or probe for measuring the mRNA or cDNA of dlk gene.
  • the present invention still further provides use of an antibody or an antigen-binding fragment thereof, which undergoes antigen-antibody reaction with extracellular domain of dlk for the production of a diagnostic for liver cancer.
  • the present invention still further provides a therapeutic drug for cancer, comprising as an effective ingredient an antibody which undergoes antigen-antibody reaction with Dlk expressing on surfaces of cancer cells, the antibody exerting anticancer action against the cancer cells.
  • the present invention still further provides a method for treating cancer, comprising administering to a cancer patient an effective amount of an antibody which undergoes antigen-antibody reaction with Dlk expressing on surfaces of cancer cells and which exerts anticancer action against the cancer cells.
  • the present invention still further provides use of an antibody which undergoes antigen-antibody reaction with Dlk expressing on surfaces of cancer cells and which exerts anticancer action against said cancer cells, for the production of a therapeutic drug for cancer.
  • liver cancer which utilizes a novel liver cancer marker was provided. Since dlk is not detected in organs other than placenta in adults and since dlk is also not detected in mouse acute liver injury models, liver cancer may be detected with high specificity by the method of the present invention. Further, since dlk is expressed in the highly proliferative liver cells during fetal period and in oval cells emerging in regeneration of the liver in adults, it is thought that dlk is expressed in the growing liver cancer cells, so that it is thought that liver cancer at an early stage may be detected.
  • liver cancer since FA1 which is the extracellular domain of dlk liberated into the blood or urine may be detected by using the anti-dlk monoclonal antibody, liver cancer may be detected simply by blood test or urine test utilizing the extracellular domain of dlk as a tumor marker. Still further, a novel therapeutic drug for cancer which has a high anticancer activity was provided. The therapeutic drug for cancer according to the present invention is especially effective for therapy of liver cancer.
  • the present inventors discovered that dlk is expressed in adults on the surfaces of liver cancer cells with high specificity, and that the detection of liver cancer cells may be attained by using the dlk antigen on the cell surfaces as a tumor marker or by measuring the mRNA of dlk gene.
  • the present invention is based on this discovery.
  • the term "measurement” includes detection, quantification and semi-quantification.
  • Dlk per se is known and the cDNA encoding dlk has been cloned.
  • the nucleotide sequence thereof and the amino acid sequence encoded thereby are also known.
  • the sequence of human dlk is described in GenBank Accession Nos. U15979, NM_003836 and so on.
  • the sequence of rat dlk is described in GenBank Accession Nos. AB046763 and D84336.
  • the sequence of bovine dlk is described in GenBank Accession No. AB009278.
  • the cDNA sequence of human dlk as well as the amino acid sequence encoded thereby are shown in SEQ ID NOs: 1 and 2 of SEQUENCE LISTING. Further, as described in GenBank Accession No.
  • NM_003836 a plurality of variants having a SNP(s) are known, and needless to say, these variants are included in dlk.
  • the extracellular domain is the region from 24aa to 304aa.
  • liver cancer cells may be detected utilizing it as a tumor marker antigen.
  • Liver cancer cells include hepatocellular carcinoma cells and cholangiocellular carcinoma cells, and as will be concretely described in Examples below, it was confirmed that dlk is expressed on the cell surfaces of both of these carcinoma cells.
  • the method per se for measuring the tumor marker antigen on cell surfaces is well-known, and may be attained by various methods utilizing the antigen-antibody reaction between the tumor marker antigen and an antibody which undergoes antigen-antibody reaction therewith.
  • the antibody to be used a monoclonal antibody having a high and uniform specificity is preferred.
  • Non-patent Literature 11 An anti-mouse dlk monoclonal antibody is known (Non-patent Literature 11). Further, as will be concretely described, the present inventors succeeded in the preparation of anti-human dlk monoclonal antibodies. That is, a hybridoma which produces an anti-human dlk monoclonal antibody may be established by inserting a human dlk cDNA into an expression vector for mammalian cells, preparing a cell line which expresses dlk on cell surfaces by introducing the obtained recombinant vector into cells of a cell line, and establishing a hybridoma using the cells of the cell line as an immunogen by the well-known method by Kohler and Milstein.
  • the extracellular domain of dlk or a part thereof may easily be prepared by a genetic engineering method or by a peptide-synthesis method.
  • An anti-dlk monoclonal antibody may also be prepared by the well-known method using as an immunogen the prepared extracellular domain of dlk or a part thereof as it is, or after conjugating it to a carrier such as keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA).
  • KLH keyhole limpet hemocyanin
  • BSA bovine serum albumin
  • An antibody fragment having antigen-binding property, such as Fab fragment or F(ab') 2 fragment of the antibody may also be used.
  • liver cancer cells in a sample may be measured by well-known methods using an anti-dlk antibody.
  • the measurement methods include immunostaining, sandwich methods such as ELISA, agglutination methods such as latex agglutination method, and competitive methods. Any of these methods is well-known, and may be carried out easily according to a conventional method if the antibody to be used is obtained.
  • MACS magnetic cell sorter
  • FACS fluorescence activated cell sorter
  • FACS is an apparatus for separating the cells by labeling the cells with a fluorescence-labeled antibody, irradiating the cell flow emitted from a nozzle with a laser beam, analyzing the generated dispersed light and fluorescence, electrically charging droplets each containing one cell therein, and separating the droplets in a high electric field. Because of the same reason as MACS, FACS is also preferred to be used in the method of the present invention. Both MACS and FACS are well-known in the art and apparatuses therefor are commercially available, so that they may be easily carried out if the antibody to be used is obtained.
  • the sample to be subjected to the method for detecting dlk antigen on cell surfaces is a sample which may contain liver cancer cells, and usually is a biopsy sample of the liver.
  • the biopsy sample may be a tissue section (in case of immunostaining) or may be a cell suspension obtained by treating the liver tissue with a protease such as collagenase or trypsin.
  • Non-patent Literature 10 the extracellular domain of Dlk which is a membrane protein is cleaved off to yield a soluble molecule known as FA1 (Non-patent Literature 10).
  • the anti-human dlk monoclonal antibodies prepared by the present inventors undergo antigen-antibody reaction also with FA 1. Therefore, by immunoassaying FA1 in the blood using an anti-dlk antibody, especially anti-dlk monoclonal antibody, diagnosis of liver cancer may be attained using a blood sample (serum, plasma, whole blood and the like) or urine sample. Immunoassay per se may easily be carried out by the conventional methods described above.
  • an anti-Dlk antibody or an antigen-binding fragment thereof as a primary antibody is immobilized on a solid phase; the immobilized primary antibody is reacted with a sample; the resultant is reacted, after washing, with a secondary antibody which undergoes antigen-antibody reaction with Dlk; and, after washing, the secondary antibody bound to the solid phase is measured.
  • the secondary antibody bound to the solid phase may be measured.
  • the FA1 in a test sample may be quantified by subjecting a plurality of samples each containing a known level of FA1 to the above-described immunoassay; preparing a calibration curve based on the relationship between the each of the measured amounts of the label and each of the amounts of FA1 in standard samples; and applying the measurement result of a test sample containing an unknown amount of FA1 to the calibration curve.
  • a detection sensitivity of as high as 1 ng/mL or less may be attained by using a luminescent substance (fluorogenic peroxidase substrate: PIERCE).
  • an anti-Dlk antibody or an antigen-binding fragment thereof is immobilized on particles such as latex, the resulting particles are reacted with a sample, and absorbance is measured.
  • the absorbance is measured by the above-described method for each of a plurality of standard samples each containing a known level of FA1 and a calibration curve is prepared based on the measurement results.
  • the FA 1 in a test sample containing an unknown level of FA1 may be quantified by applying the measurement result of the sample to the calibration curve.
  • anti-dlk antibodies preferably anti-dlk monoclonal antibodies may be used for the detection of liver cancer, they have the use as a diagnostic for liver cancer.
  • Expression of dlk gene may also be determined by measuring the mRNA of dlk in the cells.
  • the measurement of mRNA in the cells may be carried out by conventional methods. That is, for example, as described in Examples below, it may be carried out by Northern blot; or by carrying out reverse transcription PCR (RT-PCR), electrophoresing the PCR product, and subjecting the resulting electrophoretic bands to Southern blot. Alternatively, it may be measured by directly amplifying the mRNA by NASBA or the like, electrophoresing the amplified product, and subjecting the resultant to Northern blot. All of these methods per se are conventional methods and the required reagents kits and apparatuses are commercially available.
  • each of the probes and primers used in the detection or amplification of the mRNA (or the cDNA obtained by using the mRNA as a template) of Dlk preferably has a sequence complementary to either chain of the mRNA or cDNA of Dlk, it is possible to use a probe or primer having a mismatch(es) in the number of not more than 10%, preferably not more than 5% of its size.
  • a desired restriction site may be given to the amplification product.
  • a restriction site may be convenient in inserting the amplification product into a vector.
  • the size of the probe or primer (the size of the region which hybridizes with the mRNA or cDNA of Dlk) is not restricted, and is not less than 15 bases, preferably not less than 20 bases as in the conventional methods.
  • the upper limit of the size is not restricted and the size is usually not more than 50 bases, preferably not more than 40 bases. In case of a probe, one having a size of the full length or less is appropriate.
  • nucleic acid fragment contains a region which hybridizes with a region in the mRNA or cDNA of Dlk to be measured and can be used as a primer or probe
  • a non-complementary sequence may be attached to an end of the nucleic acid fragment. Such an additional sequence may be used for the binding with a tag or another nucleic acid.
  • the present invention also provides a nucleic acid for detecting liver cancer, which hybridizes with the mRNA or cDNA of Dlk, such as these probes and primers.
  • the therapeutic drug for cancer according to the present invention contains as an effective ingredient an antibody which undergoes antigen-antibody reaction with Dlk expressing on cancer cell surfaces.
  • anti-Dlk antibodies each of which exerts anticancer activity against the cancer cells expressing Dlk on cell surfaces may be used as the antibody which undergoes antigen-antibody reaction with Dlk, and monoclonal antibodies having a high and uniform specificity are preferred.
  • the anti-dlk monoclonal antibody which exerts anticancer activity against the cancer cells expressing Dlk on their surfaces may be screened by the MTT assay using the cells of a Dlk-expressing cell line, which assay is concretely described in Examples below.
  • an anti-dlk monoclonal antibody which exerts anticancer agent against the cancer cells expressing Dlk on their surfaces may be obtained with reproducibility by the screening by MTT assay.
  • the antibody may be one derived from an animal species different from the animal species to which the therapeutic drug is to be administered, the antibody is preferably one at least whose constant region is the same constant region (Fc) of the antibody of the same animal species to which the drug is to be administered.
  • Fc constant region
  • a chimeric antibody or humanized antibody whose constant region at least is derived from human may preferably be employed.
  • the antigenicity of the antibody can be decreased, and occurrence of antibody-antigen reaction when the antibody is administered is decreased.
  • ADCC activity is increased.
  • a chimeric antibody is an antibody obtained by immunizing a mouse with an antigen, separating the region of the gene of the monoclonal antibody obtained, which region encodes the variable region (V region) of the antibody, that binds to the antigen, ligating the separated region to the gene encoding the constant region (C region) of an antibody derived from a human myeloma cell to prepare a chimeric gene, and expressing the obtained chimeric gene in a host cell.
  • a humanized antibody is an antibody encoded by a gene whose region encoding the antigen-binding site (CDR, complementarity-determining region) alone is transplanted to a human antibody gene, and is an antibody in which the region derived from mouse is still smaller than in chimeric antibodies.
  • CDR antigen-binding site
  • Humanized antibodies and their preparation methods are well-known, and a number of humanized antibodies are commercially available in recent years.
  • an anti-Dlk antibody exerts anticancer activity at least in the presence of complement. Since complement is contained in the blood of a patient, the anti-Dlk antibody functions as a therapeutic drug for cancer as it is. In the Examples below, although ADCC activity of the anti-human Dlk monoclonal antibody against the cells of human liver cancer cell line was not observed, this is presumably because that the Fc regions of the antibodies were derived from rat. Since CDC activity is observed, it is thought that ADCC will also be exerted if the Fc region is replaced with that of human. Although the anti-Dlk antibody may be used as it is, by conjugating the antibody with a toxin such as ricin or other anticancer agent, the so called missile therapy may also be attained.
  • a toxin such as ricin or other anticancer agent
  • the cancers cured by the therapeutic drug for cancer according to the present invention are the cancers in which Dlk is expressed on the surfaces of the cancer cells.
  • the cancers include liver cancer such as hepatocellular carcinoma and cholangiocellular carcinoma; lung small cell carcinoma; and type 1 neurofibromatosis.
  • liver cancer such as hepatocellular carcinoma and cholangiocellular carcinoma is most preferred.
  • the therapeutic drug for cancer according to the present invention is preferably administered through a parenteral route such as injection to the affected part, intravenous injection, intramuscular injection or the like.
  • the dosage per day per adult is usually about 0.001 to 100 mg, preferably about 0.01 to 50 mg, still more preferably about 0.1 to 5 mg in terms of the weight of the antibody per 1 kg of body weight.
  • the formulation may be one containing the antibody dissolved in physiological buffer, and one or more additives generally used in field of the formulation of pharmaceuticals may be added.
  • PCR primers were designed based on the information of gene sequence of human Dlk (GenBank accession No. U15979). The sequences of the prepared primers were as follows:
  • oligonucleotides encoding the Flag tag sequence were inserted into the Hind III/ Sal I site of pBluescript II SK(+) vector (STRATAGENE) (Sequences: forward side: 5'-agcttgactacaaggacgacgatgacaagtgag-3', reverse side: 5'-tcgactcacttgtcatcgtcgtccttgtagtca-3') (pBS-Flag).
  • the Eco RI/ Xho I fragment containing the human FA1 cDNA was cleaved out from pCRII-hFA1, and was inserted into the Eco RI/ Xho I site of pcDNA4/Myc-His vector (Invitrogen) (pcDNA4-hFA1).
  • This expression vector contains Myc tag and His tag sequences at the C-terminal, and human FA1 is expressed in the form of a fusion protein with Myc tag and His tag.
  • the cell lines derived from human liver cancer were JHH-6, HLF, JHH-5 and Huh-6, and all of them were furnished by Japan Health Sciences Foundation.
  • RNAs were extracted from the cells of the human cancer liver-derived cell lines using Trizol reagent (Nippon Gene). cDNAs were synthesized from the extracted RNAs using First-strand cDNA synthesis kit (Amersham Pharmacia Biotech), and expression of human Dlk was analyzed by PCR.
  • the used primers were as follows:
  • RNAs Fetal tissue total RNAs (TAKARA) and the total RNAs extracted from the cells using Trizol reagent (Nippon Gene), in an amount of 10 ⁇ g each, were electrophoresed on formaldehyde-denatured gel. After transferring the bands to a Nylon membrane, hybridization with a DIG-labeled cDNA probe was performed. Detection of the probe was carried out by chemiluminescence using CDP-star as a substrate.
  • Trizol reagent Nippon Gene
  • the above-described retrovirus vector (pMIG-hdlk-Flag) in which the human dlk gene was incorporated was introduced into BOSC23 cells ( Pear, W.S. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 8392-8396 ) that are packaging cells, to prepare a retrovirus having the human dlk gene.
  • Cells of cell line 7E2-C which we previously established from the fetal liver of a transgenic mouse producing temperature-sensitive SV40 large T antigen ( Yanai,N. et al. (1991) Exp. Cell Res. 197, 50-56 ) were infected with the produced retrovirus to obtain a cell line 7E2-C(hdlk) consistently expressing human Dlk.
  • HEK293 cells obtained from Laboratory of Cell Growth and Differentiation, Institute of Molecular and Cellular Biosciences, The University of Tokyo
  • G418 gene, GIBCO BRL
  • Rats were immunized with cells of the above-described two types of cell lines as antigens, respectively, and hybridoma clones each of which produces an anti-human Dlk monoclonal antibody were prepared by a conventional method.
  • the cells of each of these clones were intraperitoneally administered to BALB/c nude mice at a dose of 3 x 10 6 cells, respectively, which nude mice preliminarily (7 days before) received 2,6,10,14-tetramethylpentadecane (pristane), and two weeks later, ascites were recovered from the mice.
  • the anti-human Dlk monoclonal antibodies each of which was produced by each hybridoma were obtained by subjecting the ascites to caprylic acid precipitation and to purification with a protein G column.
  • the cells of the above-described 7E2-C(hdlk) cell line were placed in a gelatin-coated 96-well culture plate (Coming) in an amount of 7.5 x 10 3 cells/well, and cultured at 37°C for 2 days. After washing the plate with ice-cold PBS, the cells were fixed with 4% paraformaldehyde solution and treated with 0.2% Triton-X-100 (trademark) solution to prepare a plate for cell ELISA. Thereafter, ELISA was performed according to a conventional method. More particularly, ELISA was performed as follows. First, blocking with 1% BSA-PBS solution was carried out at room temperature for 2 hours.
  • the hybridoma supernatant was then added to the plate, and the resulting mixture was allowed to react at room temperature for 1 hour, followed by washing the plate 3 times with 0.1 % Tween 20 (trademark)-PBS solution.
  • Tween 20 trademark
  • biotinylated anti-rat IgG produced by VECTOR
  • 100-fold diluted with 0.1 % Tween 20-PBS solution was used. After allowing reaction at room temperature for 1 hour, the plate was washed 3 times with 0.1 % Tween 20-PBS solution.
  • Paraffin sections of normal human tissue and liver cancer tissue were deparaffinized and heat-treated in 10 mM sodium citrate solution for 10 minutes. The resulting sections were used for staining using the anti-human Dlk monoclonal antibodies. After performing coloring reaction with DAB (3,3'-diaminobenzidine) as a substrate, nuclear stain with hematoxylin was performed as a counter staining. More concretely, these operations were carried out as follows.
  • the sections fixed with 4% paraformaldehyde and embedded in paraffin were deparaffinized and heat-treated in 10 mM sodium citrate solution for 10 minutes.
  • the resulting sections were treated with methanol to which aqueous hydrogen peroxide solution was added to a final concentration of 0.3% at room temperature for 20 minutes to remove endogenous peroxidase activity.
  • Block Ace DAINIPPON PHARMACEUTICAL
  • paraffin sections of human hepatocellular carcinoma (CYBRDI, Hepatocellular carcinoma; catalogue No.: CS03-01, lot No.: CS03-01-001-012 (23 patients, 63 sections), CS03-01-002 (63 patients, 63 sections)) were deparaffinized, hydrophilized, and treated with 10 mM citrate buffer (pH6.0) in an autoclave (121°C, 5 minutes). The resulting sections were treated with methanol to which aqueous hydrogen peroxide solution was added to a final concentration of 0.3% at room temperature for 20 minutes to remove endogenous peroxidase activity.
  • CYBRDI Hepatocellular carcinoma
  • Cells were peeled off from the culture plate by trypsin treatment, and a cell suspension (cell population density: 5 x 10 6 cells/ml) was prepared. Then 0.5 ⁇ g of the each anti-human Dlk monoclonal antibody and 100 ⁇ L of the cell suspension were reacted at 4°C for 30 minutes. After washing the cells with PBS, the cells were reacted with biotinylated anti-rat IgG (VECTOR) (0.5 ⁇ g) and then again washed with PBS.
  • VECTOR biotinylated anti-rat IgG
  • Human FA1-expressing vector was introduced into 7E2-C cells, and the culture supernatant 3 days after thereof, or hFA1 purified from the culture supernatant by His Trap HP Kit (Amersham Bioscience) (hFA1 concentration: 30 ⁇ g/ml) was used as the detection sample.
  • Sandwich ELISA using clone 31C4 as the capture antibody and biotinylated clone 4C4 as the detection antibody was employed for the detection.
  • the biotinylation of the detection antibody was carried out using ECLTM Protein Biotinylation Module(Amersham Bioscience). More concretely, this sandwich ELISA was carried out as follows.
  • the capture antibody clone 31 C4 was diluted with PBS to 10 ⁇ g/ml, and added to a 96-well plate in an amount of 100 ⁇ l/well. After leaving the plate to stand at room temperature overnight, the plate was washed 3 times with PBS, and blocking with 2% skim milk in PBS (hereinafter referred to as "2% MPBS") was carried out at room temperature for 2 hours. Then the culture supernatant containing hFA1 or hFA1 diluted with 2% MPBS to the respective concentration was added, and the plate was left to stand at room temperature for 1 hour.
  • 2% MPBS 2% skim milk in PBS
  • biotinylated clone 4C4 as the detection antibody was added. After allowing reaction at room temperature for 1 hour, the plate was washed 3 times with 0.1 % Tween 20 (trademark)-PBS solution.
  • biotinylated anti-rat IgG VECTOR 100-fold diluted with 2% MPBS solution was used. After allowing reaction at room temperature for 1 hour, the plate was washed three times with 0.1% Tween 20-PBS solution.
  • Non-patent Literature 7, Patent Literature 1 The present inventors previously discovered that Dlk highly expresses in fetal hepatic cells, the expression is not observed in adult hepatic cells and that stem cells alone may be recovered from fetal liver with a high purity by using an anti-mouse Dlk monoclonal antibody in combination with MACS (magnetic beads cell sorting) (Non-patent Literature 7, Patent Literature 1). Thus, whether Dlk shows the similar expression pattern in human or not was first investigated. By Northern blot analysis of total RNA sample (TAKARA) from human fetal liver, expression of human Dlk was observed in fetal liver during the 6th to 12th week of pregnancy (Fig. 1A). Expression of human Dlk was also investigated in various fetal organs at 12th week of pregnancy.
  • TAKARA total RNA sample
  • the present inventors first prepared anti-human Dlk monoclonal antibodies (rat IgG). Two types of human Dlk-expressing cells as antigens were established, and rats were immunized with these cells as antigens. Hybridomas were prepared according to a conventional method, and positive clones were selected by FACS analysis using the 7E2-C(hdlk) cells used as the antigen and by cell ELISA. Cloning was further carried out and three stable clones (clones 1C1, 4C4 and 31 C4) were established. By FACS analysis using the each culture supernatant of the finally established clones, it was confirmed that a monoclonal antibody which specifically reacts with human Dlk was contained in each culture supernatant.
  • the cells of each of these clones were intraperitoneally administered to BALB/c nude mice at a dose of 3 x 10 6 cells, respectively, which nude mice preliminarily (7 days before) received 2,6,10,14-tetramethylpentadecane (pristane), and two weeks later, ascites were recovered from the mice.
  • the anti-human Dlk monoclonal antibodies each of which was produced by each hybridoma were obtained by subjecting the ascites to caprylic acid precipitation and to purification with a protein G column. Each of the obtained purified monoclonal antibodies showed an activity comparable to that observed for each culture supernatant in FACS analysis.
  • RT-PCR Analysis by RT-PCR was then carried out. From the total RNAs extracted from each of the cell lines, cDNAs were synthesized, and PCR was performed using the obtained cDNAs as templates. As a result, similar to the results of the FACS analysis and immunostaining, expression of human Dlk was observed in the differentiated type cell lines. However, by the RT-PCR, expression of human Dlk was also observed in the undifferentiated type cell lines even though it was weak (Fig. 2C), which was not observed in FACS analysis and immunostaining. The difference between the results with the differentiated type cell lines is thought to stem from the difference in the detection sensitivities.
  • each cell suspension of the two types of Dlk-expressing cell lines 7E2-C(hdlk) and HEK293(hdlk) was mixed with an immunization aid (Freund's complete adjuvant: WAKO PURE CHEMICALS) at a ration of 1:1, and the obtained emulsion was injected to both feet of a Wister rat of 6 week age in an amount of 1 x 10 7 cells/foot, thereby immunizing the animal.
  • lymph nodes of the both legs were recovered, lymphocytes were prepared therefrom, and cell fusion with mouse myeloma cell line (P3X) was carried out by the polyethylene glycol method.
  • the fused cells were incubated in a medium containing HAT (aminopterin, hypoxanthine, thymidine) in a 96-well flat-bottomed plate under 5% CO 2 in an incubator. After the culturing, the culture supernatants of the grown hybridomas were subjected to screening by FACS analysis and cell ELISA using 7E2-C(hdlk) cell lines, thereby selecting positive clones. These clones were further cloned to establish 3 types of hybridoma (clones 1C1, 4C4 and 31C4). These hybridomas were separately suspended in RPMI medium to a population density of 1.5 x 10 7 cells/ml.
  • HAT amopterin, hypoxanthine, thymidine
  • Each of the cell suspensions was intraperitoneally administered to BALB/c nude mice (Balb/c-nu/nuSlc) in an amount of 200 ⁇ L (3 x 10 6 cells), which nude mice preliminarily received 2,6,10,14-tetramethylpentadecane (pristane) 7 days before, and ascites were recovered from the mice two weeks later.
  • the anti-human Dlk monoclonal antibodies each of which was produced by each hybridoma were obtained by subjecting the ascites to caprylic acid precipitation and to purification with a protein G column. Each of the obtained purified monoclonal antibodies showed an activity comparable to that observed for each culture supernatant in FACS analysis.
  • Venous blood was collected in the presence of heparin from a healthy individual, and after being 2-fold diluted with PBS, overlaid on Lymphoprep (DAIICHI PURE CHEMICALS), followed by centrifugation at 20°C at 800 x g for 20 minutes. After the centrifugation, mononuclear cells in the intermediate fraction were collected and washed three times with PBS, followed by being suspended in DMEM medium supplemented with 10% FCS, which mononuclear cells were used as effector cells.
  • DAIICHI PURE CHEMICALS Lymphoprep
  • Venous blood from a healthy individual was collected in the absence of an anticoagulant and transferred to a 15 ml tube.
  • the blood was incubated in an incubator at 37°C for 60 minutes and then left to stand at room temperature for 60 minutes, followed by centrifugation at 20°C, at 2500 rpm for 15 minutes after peeling off the clot from the wall of the tube. After the centrifugation, the supernatant serum was recovered and used as a complement-containing serum. The serum heated at 56°C for 30 minutes to inactivate the complement was used as a control.
  • TetraColor ONE SEIKAGAKU CORPORATION
  • reaction was allowed to occur under 5% CO 2 in an incubator for 3 to 4 hours.
  • the 96-well plate was set in a microplate reader as it was and absorbance at 490 nm (control wavelength: 655 nm) was measured.
  • HEK293 cells and HEK293(hdlk) cells were peeled off from the plate by trypsinization and the cells were suspended to a population density of 1 x 10 5 cells/ml in DMEM medium supplemented with 10% FCS, which were used as target cells.
  • the cells were inoculated in a gelatin-coated 96-well flat-bottomed plate to a density of 1 x 10 4 cells/well, and cultured in the presence of anti-human Dlk antibody 4C4 or 31C4, and rat IgG (0.2, 1.0 and 5.0 ⁇ g/ml), respectively, for 30 minutes. Then the human serum used as a complement was added to an amount of 25% of the culture medium, and the cells were cultured for 72 hours.
  • absorbance was measured by the MTT assay.
  • the absorbance indicating the number of living cells under CDC activity was calculated by subtracting the mean value of the live cells in the well to which the complement-containing serum was added to the culture medium.
  • Statistical significance test was carried out by the Student's t test.
  • Huh-7EGFP cells and Huh-7(hdlk) cells were peeled off from the plate by trypsinization and the cells were suspended to a population density of 2 x 10 5 cells/ml in DMEM medium supplemented with 10% FCS, which were used as target cells.
  • the cells were inoculated in a 96-well flat-bottomed plate to a density of 1 x 10 4 cells/well, and cultured in the presence of anti-human Dlk antibody 4C4 or 31 C4, and rat IgG (0.3, 1, 3, 5 and 10 ⁇ g/ml), respectively, for 30 minutes. Then the human serum used as a complement was added to an amount of 25% of the culture medium, and the cells were cultured for 72 hours.
  • absorbance was measured by the MTT assay.
  • the absorbance indicating the number of living cells under CDC activity was calculated by subtracting the mean value of the live cells in the well in which the complement-containing serum was added to the culture medium.
  • Statistical significance test was carried out by the Student's t test.
  • HEK293 cells and HEK293(hdlk) cells were peeled off from the plate by trypsinization and the cells were suspended to a population density of 2 x 10 5 cells/ml in DMEM medium supplemented with 10% FCS, which were used as target cells.
  • the cells were inoculated in a gelatin-coated 96-well flat-bottomed plate in an amount of 1 x 10 4 cells/well, and cultured in the presence of anti-human Dlk antibody 1C1, 4C4 or 31C4, and rat IgG (5 ⁇ g/ml), for 30 minutes.
  • the effector cells were added to the target cells at an effector:target ratio of 20:1, 10:1 and 5:1, respectively, and the cells were cultured under 5% CO 2 in an incubator for 72 hours. After the culturing, absorbance was measured by the MTT assay. The absorbance indicating the number of living cells under ADCC activity was calculated by subtracting the mean value of the live cells in the well in which the culture medium alone was added as a control. Significant test was carried out by the Student's t test.
  • the expression vector (pcDNA-hdlk-Flag) described in "1. Materials and Methods, (1) Isolation of Full Length Human dlk cDNA and Construction of Expression Vector" in Example 1, in which the full length cDNA of human Dlk was inserted, was introduced into cells of the cell line Huh-7 derived from human liver cancer (obtained from Laboratory of Cell Growth and Differentiation, Institute of Molecular and Cellular Biosciences, The University of Tokyo), and after selection with G418 (geneticin, GIBCO BRL), two types of cell lines Huh-7(hDlk) (clones PC14 and PC16) which stably express human Dlk were established.
  • a cell line Huh-7 EGFP which stably expresses EGFP was established by introducing an expression vector (PEGFP) in which the full length cDNA of EGFP was incorporated, into Huh-7 cells and by selection with G418.
  • PEGFP expression vector
  • Venous blood was collected from a male Std:Wister/ST rat of 8-week age in the absence of an anticoagulant, and complement-containing serum was separated by the method described in "1. Materials and Methods, (11) Separation of Human Complement-containing Serum" in Example 2.
  • Dlk is expressed on human cancer cell lines and cancer tissues suggest the possibility that Dlk may be used as a tumor marker and an anti-human Dlk monoclonal antibody may be used as a therapeutic antibody targeting cancer cells expressing Dlk.
  • cytotoxicity by the antibody and complement that is, CDC activity was measured (Fig. 8, Tables 3.1 and 3.2).
  • HEK293 cells or HEK293(hdlk) cells, as target cells were inoculated in a 96-well plate, and the anti-human Dlk antibody (clone 4C4 or 31 C4 was added to a level of 5 ⁇ g/ml) and the complement-containing serum were added, followed by culturing the cells.
  • the absorbance of the system to which the anti-human Dlk antibody (clone 31 C4) was added to a level of 5 ⁇ g/ml was the same as the system to which no antibody was added or the control antibody was added, and the number of live cells was about the same (Fig. 8A, Table 3.1). Further, no antibodies showed cytotoxicity activity against the HEK293 cells not expressing Dlk.
  • HEK293(hdlk) cells under a microscope revealed that with the system in which the control IgG antibody was added to the complement-containing serum, or in which the anti-human Dlk antibody (clone 31C4) was added to the inactivated complement-containing serum, the cells formed colonies and grew. In contrast, in the system in which the anti-human Dlk antibody (clone 31 C4) was added to the complement-containing serum, most of the cells were dispersed and seemed to be dead. On the other hand, as for HEK293 cells not expressing Dlk, no injured cells were observed even in the system where the anti-human Dlk antibody and the complement-containing serum were added.
  • the CDC activity on the HEK293(hdlk) cells when the anti-human Dlk antibody (clone 4C4 or 31 C4) was added to a level of 0.2, 1.0 or 5 ⁇ g/ml) was examined (Fig. 8B, Table 3.2).
  • Fig. 8B Table 3.2
  • the number of live HEK293(hdlk) cells decreased in a dose-dependent manner of anti-human Dlk antibody, and that the activity of 31 C4 was higher than that of 4C4.
  • ADCC activities of the prepared anti-human Dlk monoclonal antibodies were measured using the HEK293(hdlk) cells expressing human Dlk as target cells, and using mononuclear cells in the peripheral blood from a healthy individual as effector cells.
  • HEK293 or HEK293(hdlk) cells were cultured together with the anti-human Dlk monoclonal antibody (clone 1C1, 4C4 or 31C4) and human peripheral blood mononuclear cells, and three days later, the injury of the target cells in each well was measured by MTT assay.
  • the effector:target ratio was 20:1, 10:1 or 5:1.
  • the effector:target ratio was 10:1, the activity on HEK293(hdlk) cells, where any of the anti-human Dlk antibodies was added, was similar to the cases where no antibody was added or the control antibody was added, and the activity on HEK293 cells was also similar (Fig. 9, Table 4).
  • Cytotoxicity by the antibody and complement was measured using Huh-7EGFP cells and Huh-7(hdlk) cells (clones PC14 and PC16) (Fig. 11, Table 5).
  • the cells were inoculated in a 96-well plate, and the anti-human Dlk antibody (clone 4C4 or 31C4 was added to a level of 5 ⁇ g/ml) and the complement-containing serum were added, followed by culturing the cells. Three days after the beginning of the culturing, injury of the target cells were assayed by the MTT assay.
  • the absorbance was decreased and 24 to 94% decrease in the number of live cells were observed in the system where the anti-Dlk antibody (clone 4C4 or 31 C4) was added, when compared with the system where no antibody was added or the control IgG antibody was added. No antibodies showed cytotoxicity activity against the Huh-7 EGFP cells not expressing Dlk (Fig. 11A, Table 5A).
  • CDC activities on Huh-7(hdlk) cells where the anti-human Dlk antibody (clone 4C4 or 31C4) was added to a level of 0.3, 1, 3, 5 or 10 ⁇ g/ml were examined (Fig. 11B, Table 5B).
  • Measurement of CDC activities by MTT assay at three days after the beginning of the culturing revealed that both of the antibodies 4C4 and 31 C4 killed Huh-7(hdlk) cells dose-dependently.
  • the anti-human Dlk monoclonal antibodies showed complement-dependent cytotoxicity against the cells of Huh-7 cell line derived from human liver cancer, by which the cells were killed. Since expression of Dlk is observed in the cancerous parts of human liver cancer cells, the prepared monoclonal antibodies are effective as therapeutic antibodies which kill the liver cancer cells expressing Dlk.
  • the anti-human dlk monoclonal antibody clone 1C1 although neither the CDC activity nor ADCC activity has been observed, since it strongly recognizes the Dlk antigen on the cells of the human liver cancer cell lines and on the liver cancer pathologic sections as described in "2.
  • an anti-dlk monoclonal antibody which exerts anticancer action may be prepared by forming a chimeric antibody or humanized antibody in which at least the constant region is derived from human Fc.
  • the method for detecting liver cancer and the diagnostic drug for liver cancer according to the present invention are useful for the diagnosis of liver cancer.
  • the therapeutic drug for cancer according to the present invention is useful for therapies of cancers such as liver cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP04819413A 2003-11-28 2004-11-25 Methode de detection, diagnostic et remede contre le cancer du foie Active EP1702982B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10003331A EP2204448B1 (fr) 2003-11-28 2004-11-25 Procédé de détection du cancer du foie, diagnostic de cancer du foie et remède contre le cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003399331 2003-11-28
JP2003401585 2003-12-01
JP2003423237 2003-12-19
PCT/JP2004/017499 WO2005052156A1 (fr) 2003-11-28 2004-11-25 Methode de detection, diagnostic et remede contre le cancer du foie

Publications (3)

Publication Number Publication Date
EP1702982A1 true EP1702982A1 (fr) 2006-09-20
EP1702982A4 EP1702982A4 (fr) 2007-04-25
EP1702982B1 EP1702982B1 (fr) 2010-05-05

Family

ID=34636972

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10003331A Active EP2204448B1 (fr) 2003-11-28 2004-11-25 Procédé de détection du cancer du foie, diagnostic de cancer du foie et remède contre le cancer
EP04819413A Active EP1702982B1 (fr) 2003-11-28 2004-11-25 Methode de detection, diagnostic et remede contre le cancer du foie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10003331A Active EP2204448B1 (fr) 2003-11-28 2004-11-25 Procédé de détection du cancer du foie, diagnostic de cancer du foie et remède contre le cancer

Country Status (8)

Country Link
US (2) US20080112956A1 (fr)
EP (2) EP2204448B1 (fr)
JP (1) JP4695982B2 (fr)
AT (2) ATE466937T1 (fr)
CA (1) CA2552553C (fr)
DE (1) DE602004027085D1 (fr)
ES (2) ES2345493T3 (fr)
WO (1) WO2005052156A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2096122A1 (fr) * 2006-11-10 2009-09-02 Livtech Inc. Anticorps anti-humain specifiques de dlk1 presentant une activite anti-tumorale in vivo
US8017118B2 (en) 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
WO2012138102A2 (fr) * 2011-04-04 2012-10-11 한국생명공학연구원 Anticorps humains spécifiques de dlk1 et compositions pharmaceutiques les contenant
US9303086B2 (en) 2012-10-03 2016-04-05 Livtech, Inc. Anti-hDlk-1 antibody having an antitumor activity in vivo

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100964193B1 (ko) * 2009-04-17 2010-06-16 씨비에스바이오사이언스 주식회사 간암 예후 마커
BR112012029281B1 (pt) 2010-05-17 2020-12-08 Livtech, Inc anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
EP2412792A1 (fr) 2010-07-29 2012-02-01 The Procter & Gamble Company Composition de détergent liquide
WO2012138100A2 (fr) * 2011-04-04 2012-10-11 한국생명공학연구원 Inhibiteurs du récepteur de type ii b de l'activine comportant un domaine soluble dans l'eau extracellulaire dlk1
CN102778566B (zh) * 2011-05-07 2016-01-13 上海市肿瘤研究所 Dlk1在肝癌诊断及预后判断中的应用
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
UA119458C2 (uk) 2014-05-15 2019-06-25 Ейсей Р Енд Д Менеджмент Ко., Лтд. Сполуки піридину пладієноліду та способи застосування
MD3377485T2 (ro) 2015-11-18 2020-02-29 Eisai R&D Man Co Ltd Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare
CN110031629B (zh) * 2018-01-11 2020-08-18 上海交通大学 检测人血清dlk1蛋白的elisa试剂盒及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013762A2 (fr) * 1992-12-11 2000-06-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Gène du type delta exprimé dans des tumeurs neuro-endocriniennes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185815A1 (en) * 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
DE60229242D1 (de) 2001-05-16 2008-11-20 Kanagawa Kagaku Gijutsu Akad Verfahren zum nachweis und zur trennung undifferenzierter leberzellen mit dlk
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004048938A2 (fr) * 2002-11-26 2004-06-10 Protein Design Labs, Inc. Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013762A2 (fr) * 1992-12-11 2000-06-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Gène du type delta exprimé dans des tumeurs neuro-endocriniennes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FLORIDON C ET AL: "Does fetal antigen 1 (FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? A study of FA1 in embryonic, fetal, and placental tissue and in maternal circulation" DIFFERENTIATION, SPRINGER VERLAG, DE, vol. 66, no. 1, August 2000 (2000-08), pages 49-59, XP002223507 ISSN: 0301-4681 *
LABORDA J ET AL: "dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 268, no. 6, 25 February 1993 (1993-02-25), pages 3817-3829, XP002144816 ISSN: 0021-9258 *
See also references of WO2005052156A1 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2096122A1 (fr) * 2006-11-10 2009-09-02 Livtech Inc. Anticorps anti-humain specifiques de dlk1 presentant une activite anti-tumorale in vivo
EP2096122A4 (fr) * 2006-11-10 2010-11-10 Livtech Inc Anticorps anti-humain specifiques de dlk1 presentant une activite anti-tumorale in vivo
US8227578B2 (en) 2006-11-10 2012-07-24 Abe, Ikubo & Katayama Anti-human dlk-1 antibody showing anti-tumor activity in vivo
AU2007318483B2 (en) * 2006-11-10 2013-05-02 Livtech Inc. Anti-human Dlk-1 antibody showing anti-tumor activity in vivo
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
US8017118B2 (en) 2008-03-17 2011-09-13 LivTech Inc. — Teikyo University Biotechnology Research Center Anti-hDlk-1 antibody having an antitumor activity in vivo
EP2275537A4 (fr) * 2008-03-17 2013-02-13 Livtech Inc ANTICORPS ANTI-HUMAIN SPÉCIFIQUES DE DLK1 PRÉSENTANT UNE ACTIVITÉ ANTI-TUMORALE IN VIVO& xA;
WO2012138102A2 (fr) * 2011-04-04 2012-10-11 한국생명공학연구원 Anticorps humains spécifiques de dlk1 et compositions pharmaceutiques les contenant
WO2012138102A3 (fr) * 2011-04-04 2013-01-10 한국생명공학연구원 Anticorps humains spécifiques de dlk1 et compositions pharmaceutiques les contenant
US9303086B2 (en) 2012-10-03 2016-04-05 Livtech, Inc. Anti-hDlk-1 antibody having an antitumor activity in vivo

Also Published As

Publication number Publication date
ATE546527T1 (de) 2012-03-15
EP1702982B1 (fr) 2010-05-05
EP1702982A4 (fr) 2007-04-25
US20080112956A1 (en) 2008-05-15
ES2345493T3 (es) 2010-09-24
WO2005052156A1 (fr) 2005-06-09
JP4695982B2 (ja) 2011-06-08
EP2204448B1 (fr) 2012-02-22
CA2552553C (fr) 2015-01-06
EP2204448A1 (fr) 2010-07-07
DE602004027085D1 (de) 2010-06-17
ATE466937T1 (de) 2010-05-15
US20100151503A1 (en) 2010-06-17
JPWO2005052156A1 (ja) 2007-12-06
ES2382987T3 (es) 2012-06-15
CA2552553A1 (fr) 2005-06-09

Similar Documents

Publication Publication Date Title
US20100151503A1 (en) Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer
US10696743B2 (en) Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
US9296823B2 (en) Diagnosis and treatment of cancer using anti-GPR49 antibody
KR102029248B1 (ko) 암세포 특이적 항체, 항암제 및 암 검사 방법
US20200157231A1 (en) Diagnosis and treatment of cancer using anti-lgr7 antibody
CA2669731A1 (fr) Anticorps anti-humain specifiques de dlk1 presentant une activite anti-tumorale in vivo
WO2014192974A1 (fr) Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer
MX2011006895A (es) Pasta de papel de fibra mejorada.
JPWO2018181656A1 (ja) 抗ｇｐｒ２０抗体
US20220381787A1 (en) Novel lox-1 antibody compositions, lox1 neutralization assay and methods of treatment using same
WO2024003310A1 (fr) Méthodes de diagnostic et de traitement de la leucémie lymphoblastique aiguë
AU2014201680A1 (en) Diagnosis and treatment of cancer using anti-GPR49 antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070328

17Q First examination report despatched

Effective date: 20080227

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004027085

Country of ref document: DE

Date of ref document: 20100617

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100505

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2345493

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100806

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100906

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110208

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004027085

Country of ref document: DE

Effective date: 20110207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101125

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101106

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100805

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20170928 AND 20171004

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004027085

Country of ref document: DE

Representative=s name: LEINWEBER & ZIMMERMANN PATENTANWALTS-PARTG MBB, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004027085

Country of ref document: DE

Representative=s name: LEINWEBER & ZIMMERMANN, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004027085

Country of ref document: DE

Owner name: KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND T, JP

Free format text: FORMER OWNER: KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY, KAWASAKI, KANAGAWA, JP

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND TECHN

Effective date: 20171218

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND T, JP

Effective date: 20180105

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230320

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231123

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231124

Year of fee payment: 20

Ref country code: FR

Payment date: 20231120

Year of fee payment: 20

Ref country code: DE

Payment date: 20231121

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240124

Year of fee payment: 20